Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
企業コードSLNO
会社名Soleno Therapeutics Inc
上場日Oct 23, 2014
設立日1999
最高経営責任者「CEO」Dr. Anish Bhatnagar, M.D.
従業員数92
証券種類Ordinary Share
決算期末Oct 23
本社所在地100 Marine Parkway, Suite 400
都市REDWOOD CITY
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94065
電話番号16502138444
ウェブサイトhttps://soleno.life/
企業コードSLNO
上場日Oct 23, 2014
設立日1999
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし